ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
0,00%
Bitcoin
67.726,45
0,00%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Evelo Biosciences Inc (EVLO)

  7. Evelo Biosciences Inc (EVLO) News

EVLO

Evelo Biosciences (EVLO)

Evelo Biosciences Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:EVLO
DatumZeitQuelleÜberschriftSymbolFirma
26/01/202423h30Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:EVLOEvelo Biosciences Inc
26/01/202423h29Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:EVLOEvelo Biosciences Inc
26/01/202423h28Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:EVLOEvelo Biosciences Inc
26/01/202423h27Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:EVLOEvelo Biosciences Inc
26/01/202423h26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVLOEvelo Biosciences Inc
12/12/202313h43Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:EVLOEvelo Biosciences Inc
12/12/202313h42Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:EVLOEvelo Biosciences Inc
04/12/202312h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVLOEvelo Biosciences Inc
01/12/202313h11Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:EVLOEvelo Biosciences Inc
21/11/202312h44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVLOEvelo Biosciences Inc
09/11/202323h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EVLOEvelo Biosciences Inc
09/11/202302h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
09/11/202302h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
09/11/202302h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
03/11/202321h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
03/11/202321h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
03/11/202321h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
27/10/202323h24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVLOEvelo Biosciences Inc
17/10/202313h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVLOEvelo Biosciences Inc
17/10/202313h00GlobeNewswire Inc.Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate PsoriasisNASDAQ:EVLOEvelo Biosciences Inc
14/09/202302h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
14/09/202302h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
14/09/202302h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
21/08/202323h25Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:EVLOEvelo Biosciences Inc
21/08/202323h25Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:EVLOEvelo Biosciences Inc
21/08/202313h43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVLOEvelo Biosciences Inc
18/08/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:EVLOEvelo Biosciences Inc
14/08/202314h14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EVLOEvelo Biosciences Inc
14/08/202313h42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVLOEvelo Biosciences Inc
14/08/202313h30GlobeNewswire Inc.Evelo Biosciences Announces Second Quarter Financial Results and Recent Business HighlightsNASDAQ:EVLOEvelo Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:EVLO

Kürzlich von Ihnen besucht

COIN
CDRTETH
COIN
LKEGBP
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten